Articles with public access mandates - Mark ShackletonLearn more
Not available anywhere: 6
Whole–genome characterization of chemoresistant ovarian cancer
AM Patch, EL Christie, D Etemadmoghadam, DW Garsed, J George, ...
Nature 521 (7553), 489-494, 2015
Mandates: National Health and Medical Research Council, Australia, Cancer Research UK …
Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma
X Zhang, JZ Tang, IA Vergara, Y Zhang, P Szeto, L Yang, C Mintoff, ...
Molecular Cancer Research 17 (7), 1435-1449, 2019
Mandates: National Health and Medical Research Council, Australia
Post‐operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre‐operative treatment and elective indication
M He, J Lovell, BL Ng, J Spillane, D Speakman, MA Henderson, ...
Journal of Surgical Oncology 111 (8), 980-984, 2015
Mandates: National Health and Medical Research Council, Australia
Stereotactic radiation therapy combined with immunotherapy against metastatic melanoma: long-term results of a phase 1 clinical trial
G Ratnayake, S Reinwald, M Shackleton, M Moore, M Voskoboynik, ...
International Journal of Radiation Oncology* Biology* Physics 108 (1), 150-156, 2020
Mandates: National Health and Medical Research Council, Australia
Parity reduces mammary repopulating activity but does not affect mammary stem cells defined as CD24+ CD29/CD49fhi in mice
GV Dall, J Vieusseux, Y Seyed-Razavi, N Godde, M Ludford-Menting, ...
Breast cancer research and treatment 183, 565-575, 2020
Mandates: National Health and Medical Research Council, Australia
Patient-derived xenografting of human melanoma
SE Boyle, CG Fedele, M Shackleton
Patient Derived Tumor Xenograft Models, 341-363, 2017
Mandates: National Health and Medical Research Council, Australia
Available somewhere: 46
Efficient tumour formation by single human melanoma cells
E Quintana, M Shackleton, MS Sabel, DR Fullen, TM Johnson, ...
Nature 456 (7222), 593-598, 2008
Mandates: US National Institutes of Health, Howard Hughes Medical Institute
Purification and unique properties of mammary epithelial stem cells
J Stingl, P Eirew, I Ricketson, M Shackleton, F Vaillant, D Choi, HI Li, ...
Nature 439 (7079), 993-997, 2006
Mandates: Genome Canada
Pan-cancer analysis of whole genomes
Nature 578 (7793), 82-93, 2020
Mandates: US National Institutes of Health, Cancer Research UK, UK Medical Research …
Heterogeneity in cancer: cancer stem cells versus clonal evolution
M Shackleton, E Quintana, ER Fearon, SJ Morrison
Cell 138 (5), 822-829, 2009
Mandates: Howard Hughes Medical Institute
Whole-genome landscapes of major melanoma subtypes
NK Hayward, JS Wilmott, N Waddell, PA Johansson, MA Field, K Nones, ...
Nature 545 (7653), 175-180, 2017
Mandates: US Department of Energy, National Health and Medical Research Council …
Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized
E Quintana, M Shackleton, HR Foster, DR Fullen, MS Sabel, TM Johnson, ...
Cancer cell 18 (5), 510-523, 2010
Mandates: US National Institutes of Health, Howard Hughes Medical Institute
Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing
I Cortés-Ciriano, JJK Lee, R Xi, D Jain, YL Jung, L Yang, D Gordenin, ...
Nature genetics 52 (3), 331-341, 2020
Mandates: US National Institutes of Health, European Commission
MDM4 is a key therapeutic target in cutaneous melanoma
A Gembarska, F Luciani, C Fedele, EA Russell, M Dewaele, S Villar, ...
Nature medicine 18 (8), 1239-1247, 2012
Mandates: US National Institutes of Health, National Health and Medical Research …
Steroid hormone receptor status of mouse mammary stem cells
ML Asselin-Labat, M Shackleton, J Stingl, F Vaillant, NC Forrest, ...
Journal of the National Cancer Institute 98 (14), 1011-1014, 2006
Mandates: Genome Canada
UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas
SQ Wong, K Waldeck, IA Vergara, J Schröder, J Madore, JS Wilmott, ...
Cancer research 75 (24), 5228-5234, 2015
Mandates: National Health and Medical Research Council, Australia
Antisense oligonucleotide–mediated MDM4 exon 6 skipping impairs tumor growth
M Dewaele, T Tabaglio, K Willekens, M Bezzi, SX Teo, DHP Low, CM Koh, ...
The Journal of clinical investigation 126 (1), 68-84, 2016
Mandates: National Health and Medical Research Council, Australia, Research Foundation …
Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA
L Tan, S Sandhu, RJ Lee, J Li, J Callahan, S Ftouni, N Dhomen, ...
Annals of Oncology 30 (5), 804-814, 2019
Mandates: National Health and Medical Research Council, Australia, Cancer Research UK …
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
R Ramsdale, RN Jorissen, FZ Li, S Al-Obaidi, T Ward, KE Sheppard, ...
Science signaling 8 (390), ra82-ra82, 2015
Mandates: National Health and Medical Research Council, Australia
HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells
CC Carter, LA McNamara, A Onafuwa-Nuga, M Shackleton, J Riddell, ...
Cell host & microbe 9 (3), 223-234, 2011
Mandates: US National Institutes of Health, Howard Hughes Medical Institute
Publication and funding information is determined automatically by a computer program